A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
Inclusion Criteria:
Exclusion Criteria:
Hartford, Connecticut 06106, United States
Minneapolis, Minnesota 55455, United States
New Hyde Park, New York 11042-2057, United States
Charleston, South Carolina 29425, United States
Milwaukee, Wisconsin 53226, United States
Winnipeg, Manitoba R3E 3P4, Canada
Hradec Králové, Hradec Kralove 500 05, Czechia
Ústí nad Labem, 401 13, Czechia
Dresden, Saxony 01307, Germany
Milan, Milano 20122, Italy
Kaunas, 50161, Lithuania
Cluj-Napoca, Cluj 400177, Romania
Timișoara, Timiș County 500063, Romania
Ferrol, A Coruna 15405, Spain
Santiago de Compostela, A Coruna 15706, Spain
Derby, Derbyshire DE22 3NE, United Kingdom
Sheffield, England S10 2TH, United Kingdom
London, Greater London E1 2ES, United Kingdom
Southampton, Hampshire SO16 6YD, United Kingdom
Birmingham, B4 6NH, United Kingdom
Cambridge, CB2 0QQ, United Kingdom
Newcastle upon Tyne, NE7 7DN, United Kingdom